6547 Stock Overview A biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Medigen Vaccine Biologics Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Medigen Vaccine Biologics Historical stock prices Current Share Price NT$49.05 52 Week High NT$66.00 52 Week Low NT$33.70 Beta 0.79 1 Month Change 36.06% 3 Month Change 15.82% 1 Year Change -18.25% 3 Year Change -71.31% 5 Year Change 134.24% Change since IPO 130.89%
Recent News & Updates
Medigen Vaccine Biologics Corporation Announces Withdrawal of New Drug Application of MVC EV71 Vaccine (Envacgen) in Malaysia Jan 11
New minor risk - Share price stability Jan 10
Medigen Vaccine Biologics Corporation to Report Q3, 2024 Results on Nov 04, 2024 Oct 26
Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Less than half of directors are independent Jun 25
Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 27 See more updates
Medigen Vaccine Biologics Corporation Announces Withdrawal of New Drug Application of MVC EV71 Vaccine (Envacgen) in Malaysia Jan 11
New minor risk - Share price stability Jan 10
Medigen Vaccine Biologics Corporation to Report Q3, 2024 Results on Nov 04, 2024 Oct 26
Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Less than half of directors are independent Jun 25
Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 27
Full year 2023 earnings released: NT$3.53 loss per share (vs NT$4.56 loss in FY 2022) Mar 17
Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024 Mar 09
First half 2023 earnings released: NT$1.61 loss per share (vs NT$1.41 loss in 1H 2022) Aug 17
Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review Jul 23
Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees Jun 30
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam May 25
Less than half of directors are independent Mar 15
Less than half of directors are independent Mar 10
Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand Dec 06
Third quarter 2022 earnings released: NT$0.95 loss per share (vs NT$2.16 profit in 3Q 2021) Nov 19
Investor sentiment improved over the past week Nov 04
Investor sentiment deteriorated over the past week Sep 16
Second quarter 2022 earnings released: NT$0.97 loss per share (vs NT$0.57 loss in 2Q 2021) Aug 15
Now 20% undervalued after recent price drop Aug 12
Investor sentiment deteriorated over the past week Jul 04
Now 20% undervalued after recent price drop Jul 01
MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration Jun 07
First quarter 2022 earnings released: NT$0.66 loss per share (vs NT$0.74 loss in 1Q 2021) May 17
Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine May 14
Less than half of directors are independent Apr 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 15
Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies Mar 04 Medigen Vaccine Biologics Corporation Files New Drug Application (NDA) of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration
Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020) Nov 15
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant Aug 25
Second quarter 2021 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 2Q 2020) Aug 18
First quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.75 loss in 1Q 2020) May 16
We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely Mar 31
New 90-day high: NT$112 Feb 03
Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan Jan 26
Metronic Global Berhad Provides Update on Termination of MOA with Medigen Vaccine Biologics Corporation to Obtain Exclusive Distribution Rights for MVC’s COVID-19 Vaccine Jan 08
New 90-day high: NT$110 Dec 30
Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt? Dec 15
New 90-day high: NT$107 Nov 27
Metronic Global Berhad Announces Memorandum of Agreement with Medigen Vaccine Biologics Corporation Nov 21
Medigen Vaccine Biologics Corporation and BlueWillow Biologics, Inc. Partners to Develop Intranasal Vaccine for SARS-CoV-2 Nov 11
Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October Oct 14
New 90-day low: NT$89.40 Oct 13 Shareholder Returns 6547 TW Biotechs TW Market 7D 0% 0% 0% 1Y -18.3% 14.7% 28.6%
See full shareholder returns
Return vs Industry: 6547 underperformed the TW Biotechs industry which returned 14.7% over the past year.
Return vs Market: 6547 underperformed the TW Market which returned 28.6% over the past year.
Price Volatility Is 6547's price volatile compared to industry and market? 6547 volatility 6547 Average Weekly Movement 7.1% Biotechs Industry Average Movement 4.9% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 6547's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6547's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan. It is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; FLU Quadrivalent, which is in Phase III clinical trial for the treatment of influenza viruses; dengue vaccine, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan.
Show more Medigen Vaccine Biologics Corporation Fundamentals Summary How do Medigen Vaccine Biologics's earnings and revenue compare to its market cap? 6547 fundamental statistics Market cap NT$16.12b Earnings (TTM ) -NT$640.49m Revenue (TTM ) NT$648.17m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6547 income statement (TTM ) Revenue NT$648.17m Cost of Revenue NT$204.67m Gross Profit NT$443.50m Other Expenses NT$1.08b Earnings -NT$640.49m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.95 Gross Margin 68.42% Net Profit Margin -98.81% Debt/Equity Ratio 0.6%
How did 6547 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 00:04 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medigen Vaccine Biologics Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hsuan Chen KGI Securities Co. Ltd. Yijun Chen SinoPac Securities Investment Service
Show 0 more analysts 
